Login to Your Account



Lpath in $473M Deal with Merck for Cancer Drug

By Donna Young


Thursday, October 30, 2008
Shares of Lpath Inc. soared 31 percent Wednesday on the news that the San Diego-based firm signed a deal with Merck Serono, a subsidiary of Merck KGaA, to develop an anticancer antibody that could potentially garner $473 million for Lpath. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription